The latest breast cancer news
Browsing: Breast Cancer
Updated APHINITY trial data show addition of pertuzumab to trastuzumab plus chemotherapy continues to yield clinical benefit in patients with operable HER2-positive early breast cancer
Data from six-year analysis of the APHINITY trial showed that adding pertuzumab to the previous…
New HER2 antibody-drug conjugate yielded promising clinical responses in breast cancer patients pretreated with T-DM1
The investigational HER2-targeted antibody-drug conjugate [Fam-] trastuzumab deruxtecan (T-DXd) demonstrated durable objective responses in patients…
Circulating tumour DNA may help predict recurrence in patients with early triple-negative breast cancer
The presence of circulating tumour DNA (ctDNA) in early-stage triple-negative breast cancer helped predict the…
Partial breast irradiation may be as effective as whole breast irradiation in preventing recurrence in patients with early breast cancer
A 10-year follow-up study of breast cancer patients who had been treated with accelerated partial…
Adding tucatinib to drug combination extends survival for advanced HER2-positive breast cancer patients
Researchers from The University of Texas MD Anderson Cancer Center today reported study results showing…
Breast cancer preventive effects of anastrozole persist long after stopping treatment
Breast cancer incidence among post menopausal women at high risk for developing the disease continued…
Combining atezolizumab with neoadjuvant chemotherapy does not improve pathologic complete response rates for patients with triple-negative breast cancer
The addition of the anti-PD-L1 immunotherapeutic atezolizumab to neoadjuvant chemotherapy for patients with triple-negative breast…
Addition of S-1 to post-operative endocrine therapy improves outcomes for patients with hormone receptor-positive, HER2-negative breast cancer
A post-operative combination of S-1, an oral fluoropyrimidine-based drug, with endocrine therapy significantly increased invasive…
Long-term follow-up shows oestrogen alone and oestrogen plus progestin have opposite effects on breast cancer incidence in postmenopausal women
Long-term follow-up results from two large, randomised, placebo-controlled Women’s Health Initiative (WHI) trials in postmenopausal…
Neoadjuvant and adjuvant treatment with pembrolizumab improves pathologic complete response rates for patients with triple-negative breast cancer with lymph node involvement
The addition of the anti-PD-1 immunotherapeutic pembrolizumab to neoadjuvant chemotherapy and as adjuvant therapy increased…